Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 2:13:1183590.
doi: 10.3389/fcimb.2023.1183590. eCollection 2023.

Trends and challenges of multi-drug resistance in childhood tuberculosis

Zengfang Zhuang  1   2 , Lin Sun  3 , Xiaorui Song  4 , Hanzhao Zhu  1   2 , Lianju Li  1   5 , Xintong Zhou  1 , Kaixia Mi  1   2   4
Affiliations
Review

Trends and challenges of multi-drug resistance in childhood tuberculosis

Zengfang Zhuang et al. Front Cell Infect Microbiol. .

Abstract

Drug-resistant tuberculosis (DR-TB) in children is a growing global health concern, This review provides an overview of the current epidemiology of childhood TB and DR-TB, including prevalence, incidence, and mortality. We discuss the challenges in diagnosing TB and DR-TB in children and the limitations of current diagnostic tools. We summarize the challenges associated with treating multi-drug resistance TB in childhood, including limitations of current treatment options, drug adverse effects, prolonged regimens, and managing and monitoring during treatment. We highlight the urgent need for improved diagnosis and treatment of DR-TB in children. The treatment of children with multidrug-resistant tuberculosis will be expanded to include the evaluation of new drugs or new combinations of drugs. Basic research is needed to support the technological development of biomarkers to assess the phase of therapy, as well as the urgent need for improved diagnostic and treatment options.

Keywords: childhood tuberculosis; diagnostic; epidemiology; multidrug resistant; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Bloom B. R., Atun R., Cohen T., Dye C., Fraser H., Gomez G. B., et al. . (2017). “Tuberculosis,” in Major infectious diseases. Eds. Holmes K. K., Bertozzi S., Bloom B. R., Jha P. (Washington (DC: The International Bank for Reconstruction and Development / The World Bank; ). - PubMed
    1. Borrell S., Teo Y., Giardina F., Streicher E. M., Klopper M., Feldmann J., et al. . (2013). Epistasis between antibiotic resistance mutations drives the evolution of extensively drug-resistant tuberculosis. Evol. Med. Public Health 2013 (1), 65–74. doi: 10.1093/emph/eot003 - DOI - PMC - PubMed
    1. Bossu G., Autore G., Bernardi L., Buonsenso D., Migliori G. B., Esposito S. (2023). Treatment options for children with multi-drug resistant tuberculosis. Expert Rev. Clin. Pharmacol. 16 (1), 5–15. doi: 10.1080/17512433.2023.2148653 - DOI - PubMed
    1. Chen X., He G., Wang S., Lin S., Chen J., Zhang W. (2019). Evaluation of whole-genome sequence method to diagnose resistance of 13 anti-tuberculosis drugs and characterize resistance genes in clinical multi-drug resistance mycobacterium tuberculosis isolates from China. Front. Microbiol. 10. doi: 10.3389/fmicb.2019.01741 - DOI - PMC - PubMed
    1. Codlin A. J., Dao T. P., Vo L. N. Q., Forse R. J., Van Truong V., Dang H. M., et al. . (2021). Independent evaluation of 12 artificial intelligence solutions for the detection of tuberculosis. Sci. Rep. 11 (1), 23895. doi: 10.1038/s41598-021-03265-0 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances